Quince Therapeutics
Formerly AI Therapeutics/LAM Therapeutics; acquired by Quince Therapeutics (Nasdaq: QNCX) 2026-05-18 alongside a $187M private placement -- recorded under parent's ticker
QNCX · Nasdaq · United States
Share price · QNCX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when QNCX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 8 Oct 2026+9.9%
Nothing announced by QNCX that day or the session before.
- 18 Sep 2026+9.1%
Nothing announced by QNCX that day or the session before.
- 25 Aug 2026-7.6%
Nothing announced by QNCX that day or the session before.
- 29 Jul 2026+13.6%
Nothing announced by QNCX that day or the session before.
- 28 Jul 2026+8.5%
Nothing announced by QNCX that day or the session before.
- 14 Jul 2026+11.8%
Nothing announced by QNCX that day or the session before.
- 10 Feb 2026+306.2%
Nothing announced by QNCX that day or the session before.
- 30 Jan 2026-94.7%
- 16 Jan 2026+23.3%
Nothing announced by QNCX that day or the session before.
- 26 Nov 2025+29.2%
Nothing announced by QNCX that day or the session before.
Share of unusual movement by asset
For each asset, the share of QNCX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
LAM-001events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 13% |
| Sessions with no dated event | — | 87% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | mTOR (inhibitor)Small molecule | Pulmonary Hypertension Associated with Interstitial Lung DiseaseBronchiolitis Obliterans Syndrome |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $5.8M | $40M+ $65M short-term inv. | $28M-$9.8M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $5.5M | $116M+ $0 short-term inv. | $75M-$19M operating cash flow | report ↗ |
| 2026-Q1 | — | $6.8M | $18M | — | report ↗ |
| 2025-Q3 | — | $8.1M | $6.5M+ $20M short-term inv. | $13M-$9.9M operating cash flow | report ↗ |
| 2025-Q2 | — | $6.5M | $17M+ $18M short-term inv. | $16M-$11M operating cash flow | report ↗ |
| 2025-Q1 | — | $8.2M | $7.8M+ $24M short-term inv. | $15M-$9.6M operating cash flow | report ↗ |
| 2024-Q3 | — | $4.9M | $2.7M+ $45M short-term inv. | $5.5M-$7.3M operating cash flow | report ↗ |
| 2024-Q2 | — | $4.2M | $7.9M+ $52M short-term inv. | $28M-$8.7M operating cash flow | report ↗ |
| 2024-Q1 | — | $3.7M | $22M+ $46M short-term inv. | $11M-$8.3M operating cash flow | report ↗ |
| 2023-Q3 | — | $1.4M | $22M+ $62M short-term inv. | $5.3M-$4.8M operating cash flow | report ↗ |
| 2023-Q2 | — | $1.4M | $23M+ $65M short-term inv. | $4.9M-$3.8M operating cash flow | report ↗ |
| 2023-Q1 | — | $3.2M | $47M+ $43M short-term inv. | $12M-$3.6M operating cash flow | report ↗ |
| 2022-Q3 | — | $2.5M | $32M+ $63M short-term inv. | $7.9M-$6.7M operating cash flow | report ↗ |
| 2022-Q2 | — | $7.2M | $47M+ $48M short-term inv. | $17M-$15M operating cash flow | report ↗ |
| 2022-Q1 | — | $13M | $68M+ $24M short-term inv. | $22M-$16M operating cash flow | report ↗ |
| 2021-Q3 | — | $14M | $62M | $22M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $35M | $5.8M+ $12M short-term inv. | $21M-$41M operating cash flow | report ↗ |
OrphAI Therapeutics reported R&D spend of $35.38M, up 90.3% YoY, cash and equivalents of $5.81M, and a net loss of $83.98M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $19M | $6.2M+ $35M short-term inv. | $14M-$32M operating cash flow | report ↗ |
| 2023-FY | — | $9.4M | $21M+ $54M short-term inv. | $7.8M-$18M operating cash flow | report ↗ |
| 2022-FY | — | $25M | $45M+ $46M short-term inv. | $13M-$44M operating cash flow | report ↗ |
| 2021-FY | — | $61M | $70M+ $37M short-term inv. | $22M-$63M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($174K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-09 | Militello John · Chief Financial Officer | Award / grant | 80,000 | — | — | Form 4 |
| 2026-11-09 | Bonuccelli Catherine M. · director | Award / grant (derivative) | 17,000 | — | — | Form 4 |
| 2026-11-09 | PATTERSON LEONE D · director | Award / grant (derivative) | 17,000 | — | — | Form 4 |
| 2026-11-09 | Valentine James Elwood · director | Award / grant (derivative) | 17,000 | — | — | Form 4 |
| 2026-11-09 | Wise John Drayton · director | Award / grant (derivative) | 17,000 | — | — | Form 4 |
| 2026-06-11 | Senner Christopher J. · director | Award / grant (derivative) | 2,700 | — | — | Form 4 |
| 2026-06-11 | Lamond David · director | Award / grant (derivative) | 2,700 | — | — | Form 4 |
| 2026-05-18 | Roberts Brigette · director, Chief Corp. Affairs Officer | Award / grant (derivative) | 34,675 | — | — | Form 4 |